TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05748990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal insulin
Description: 160 IU insulin (Humalog) is administered intranasally using a metered spray bottle 15 minutes prior to the PET scan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal insulin
Description: 160 IU insulin (Humalog) is administered intranasally using a metered spray bottle 15 minutes prior to the PET scan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% saline is administered intranasally using a metered spray bottle 15 minutes prior to the PET scan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% saline is administered intranasally using a metered spray bottle 15 minutes prior to the PET scan.
Study: NCT06562478

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Zazen Meditation
Description: The sessions will last a maximum of 40 minutes in total, comprising 10 minutes of introduction with general practice instructions, followed by 15 minutes of Zazen meditation practice. The final 15 minutes will be allocated for participants to provide feedback on the session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Zazen Meditation
Description: The sessions will last a maximum of 40 minutes in total, comprising 10 minutes of introduction with general practice instructions, followed by 15 minutes of Zazen meditation practice. The final 15 minutes will be allocated for participants to provide feedback on the session.
Study: NCT05981040

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZYIL1 capsules 25 mg and 50 mg Placebo
Description: ZYIL1 capsules 25 mg for oral administration + matching placebo of 50 mg ZYIL1 capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZYIL1 capsules 50 mg and 25 mg Placebo
Description: ZYIL1 capsules 50 mg for oral administration + matching placebo of 25 mg ZYIL1 capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZYIL1 capsules 25 mg and ZYIL1 capsules 50 mg
Description: ZYIL1 capsules 25 mg for oral administration + ZYIL1 capsules 50 mg for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo 25 mg and Matching placebo 50 mg
Description: Matching placebo of 25 mg ZYIL1 capsule + Matching placebo of 50 mg ZYIL1 capsule
Study: NCT06489223

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orofacial Myofunctional Rehabilitation Pacifier
Description: The pacifier will be offered to the child
Study: NCT06299319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: The psilocybin used in this study meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin. The psilocybin will be administered twice during the trial, in conjunction with supportive therapy.
Study: NCT06574620

Intervention type: GENETIC
Group type: OTHER
Intervention: Genetic testing
Description: Analyses of the deoxyribonucleic acid (DNA), ribonucleic acid (RNA), proteins, and other molecules in the sample.

Intervention type: GENETIC
Group type: OTHER
Intervention: Genetic testing
Description: Analyses of the deoxyribonucleic acid (DNA), ribonucleic acid (RNA), proteins, and other molecules in the sample.
Study: NCT06338787

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FeSC
Description: Iron/yeast complex
Study: NCT06574620

Intervention type: GENETIC
Group type: OTHER
Intervention: Genetic testing
Description: Analyses of the deoxyribonucleic acid (DNA), ribonucleic acid (RNA), proteins, and other molecules in the sample.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Optional biopsy
Description: Optional collection of tumour tissue and normal tissue prior to the first dose of treatment and/or after the last dose of treatment.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Optional biopsy
Description: Optional collection of tumour tissue and normal tissue prior to the first dose of treatment and/or after the last dose of treatment.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Optional biopsy
Description: Optional collection of tumour tissue and normal tissue prior to the first dose of treatment and/or after the last dose of treatment.
Study: NCT05983445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: genakumab
Description: 200mg s.c.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo for Diprospan
Description: i.m.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo for genakumab
Description: s.c.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diprospan
Description: 7mg i.m.
Study: NCT05605756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 145 UNT [Botox]
Description: Botulinum A toxin injection: Will follow the FDA-approved guideline of the treatment of chronic migraine. The following modifications are planned: (a) Total units 145 instead of 155. (b) Number of injection sites 29 instead of 31. (c) the 6 injection sites in the trapezius muscle will be eliminated as they are irrelevant to our attempt to reduce seizure events. Instead, 4 injections will be made subcutaneously along the superior sagittal suture (see figures below), where no muscles exist and thus no muscle weakness is likely. This dose (145 Units) is well below the FDA-approved guideline on safety for adolescents and adults (no more than 10 Units/Kg or a total of 340 Units).~Botox injections will take place in the BIDMC Headache Clinic which is a part of the Arnold Pain center at 1 Brookline Place. Injections will be administered by Dr. Sait Ashina, the Director of the Headache Clinic.
Study: NCT05580094

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: general anesthesia only.
Description: induction of general anesthesia by propofol and maintenance sevoflurane.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia plus supraclavicular block.
Description: induction of general anesthesia by propofol and maintenance sevoflurane then the patients will receive the supraclavicular block with bupivacaine 0.5 ml per kg.
Study: NCT04822363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Low dose aspirin in Arms A and D and High Dose Aspirin in Arm B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Low dose aspirin in Arms A and D and High Dose Aspirin in Arm B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Low dose aspirin in Arms A and D and High Dose Aspirin in Arm B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Arms C and E

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Arms C and E
Study: NCT06259981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLY-200
Description: 2.0 g GLY-200 (4 x 0.5 g capsules) orally twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 placebo capsules orally twice daily
Study: NCT06542263

Intervention type: DEVICE
Intervention: CPAP
Description: For the non-CPAP group, the intervention includes catheter ablation and conventional treatment for AF combined with OSA; For the CPAP group, the intervention includes catheter ablation and CPAP treatment for AF combined with OSA
Study: NCT05193461

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsed mood radiofrequency on dorsal root ganglion
Description: 3) Pulsed radio frequency (PRF): PRF of the dorsal root ganglion (DRG) will be performed to all participants in this study. The procedures will be performed in the operating room under fluoroscopic guidance following radiation safety standards. The dorsal root ganglion of lumbosacral roots will be targeted. The patients will be positioned prone .Lidocaine 1% will be infiltrated at the skin entry site. A 10 cm, 22-gauge radiofrequency needle with a 5 mm curved active tip will be used. A radiculogram will be done to confirm appropriate placement and DRG will be stimulated for confirmation of the appropriate nerve root involved. Proximity of the needle to the DRG will be determined by appropriate sensory stimulation with 50 Hz (0.4-0.6 V), and motor stimulation at 2 Hz will be used to determine a threshold 1.5-2.0 times greater than the sensory threshold to avoid placement near the anterior nerve root. A pulsed lesion will be generated by applying 45 V to the DRG for 6 minutes at 42°C.
Study: NCT04308785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a dose of 1200 mg intravenously on the first day of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a dose of 1200 mg intravenously on the first day of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab will be administered at a dose of 600 mg intravenously on the first day of each 21-day cycle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to tiragolumab will be administered at a dose of 600 mg intravenously on the first day of each cycle.
Study: NCT04986982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opicapone 50 mg
Description: Opicapone (BIA 9-1067) 50 mg hard capsules. Oral administration, once daily, at least 1 hour before or after the last daily dose of L-dopa/DDCI

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo hard capsules. Oral administration, once daily, at least 1 hour before or after the last daily dose of L-dopa/DDCI
Study: NCT06106373

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iotaSOFT Insertion System
Description: robotic assistive technology for cochlear implant electrode insertion
Study: NCT05450692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: Participants will receive ceralasertib oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive durvalumab as an intravenous infusion.
Study: NCT05787821

Intervention type: DEVICE
Intervention: Total Knee Arthroplasty
Description: Total knee replacement.

Intervention type: DEVICE
Intervention: Total Knee Arthroplasty
Description: Total knee replacement.

Intervention type: DEVICE
Intervention: Total Knee Arthroplasty
Description: Total knee replacement.

Intervention type: DEVICE
Intervention: Total Knee Arthroplasty
Description: Total knee replacement.

Intervention type: DEVICE
Intervention: Total Knee Arthroplasty
Description: Total knee replacement.

Intervention type: DEVICE
Intervention: Total Knee Arthroplasty
Description: Total knee replacement.
Study: NCT05290220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib
Description: 12 mg (BW≥60 kg) or 8 mg (BW \<60 kg)
Study: NCT05632172

Intervention type: PROCEDURE
Intervention: implant insertion
Description: bone level dental implant insertion
Study: NCT05787821

Intervention type: DEVICE
Intervention: Total Knee Arthroplasty
Description: Total knee replacement.

Intervention type: DEVICE
Intervention: Total Knee Arthroplasty
Description: Total knee replacement.
Study: NCT05006443

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cardiac Magnetic Resonance
Description: a non-invasive assessment to determine severity of tricuspid regurgitation
Study: NCT05969210

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toe strengthening exercise
Description: 12 participants will be in experimental group giving them Toe strengthening exercise protocol along with running training for three weeks, measure all values before giving them protocol and after protocol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: 12 participants will be in control group they will do only there running training.
Study: NCT05011032

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Homocysteine
Description: It is an amino acid which is synthesized by the demethylation of dietary methionine. It is a highly reactive, Sulfur-containing amino acid as a by-product of metabolism of essential amino acid specifically methionine. It was proved to be a strong risk factor causing many cardiovascular diseases, neurological disturbances and other health related issues

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Homocysteine
Description: It is an amino acid which is synthesized by the demethylation of dietary methionine. It is a highly reactive, Sulfur-containing amino acid as a by-product of metabolism of essential amino acid specifically methionine. It was proved to be a strong risk factor causing many cardiovascular diseases, neurological disturbances and other health related issues

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Homocysteine
Description: It is an amino acid which is synthesized by the demethylation of dietary methionine. It is a highly reactive, Sulfur-containing amino acid as a by-product of metabolism of essential amino acid specifically methionine. It was proved to be a strong risk factor causing many cardiovascular diseases, neurological disturbances and other health related issues
Study: NCT04976972

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVIO/CORI Surgical System
Description: Total knee replacement with robotic assistance

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-robotic conventional instrumentation
Description: Total knee replacement with non-robotic conventional instrumentation
Study: NCT05455450

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye movement desensitisation and reprocessing therapy
Description: Up to 16 EMDR sessions (minimum of 8 sessions), and 1-month follow-up session, as well as attending neuropsychiatric appointments (NPC). Participants will be given the choice of attending EMDR physically face-to-face or virtually via a video-consultation platform. Sessions will normally be attended weekly, with treatment completed within 6 months. Sessions will be 60-90 minutes long. EMDR will follow the standard 8-phase protocol, with additions so that it is tailored for FND presentations. The FND-specific EMDR therapy protocol has been developed for the trial by the chief investigator.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychiatric care
Description: Standard medical care consisting of 1-3 30 minute appointments with neuropsychiatrist over the course of the 9-month trial period.

Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychiatric care
Description: Standard medical care consisting of 1-3 30 minute appointments with neuropsychiatrist over the course of the 9-month trial period.
Study: NCT06136234

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caring Contacts
Description: Caring Contacts are brief, periodic messages sent over 1 year that express unconditional care and concern

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caring Contacts
Description: Caring Contacts are brief, periodic messages sent over 1 year that express unconditional care and concern

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Best Available Resources Alone
Description: Participants will be offered information about best available resources and will receive an email summarizing the resources with links and contact information. These resources are tailored to best serve the participant based on information they share during the online survey or during conversations with study staff.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Best Available Resources Alone
Description: Participants will be offered information about best available resources and will receive an email summarizing the resources with links and contact information. These resources are tailored to best serve the participant based on information they share during the online survey or during conversations with study staff.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Best Available Resources Alone
Description: Participants will be offered information about best available resources and will receive an email summarizing the resources with links and contact information. These resources are tailored to best serve the participant based on information they share during the online survey or during conversations with study staff.
Study: NCT04828525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: adjuvant dexamethasone treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: placebo
Study: NCT05895500

Intervention type: DRUG
Intervention: Injection for SC administration (120mg/syringe)
Description: Injection

Intervention type: DRUG
Intervention: Tablet (50mg/tablet), oral
Description: Tablet
Study: NCT04909255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: use beta-3 agonist for sjogren syndrome patient

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxybutynin, tolterodine, solifenacin
Description: use anti-muscarinic agent for patient with overactive bladder syndrome
Study: NCT05577104

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Description: For patients in the NPWT group, the wound bed preparation was facilitated by vacuum-assisted closure (VAC).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional moist dressings
Description: For patients in the control group, the wound bed preparation was facilitated by conventional dressing change method (with alginates ).
Study: NCT05451888

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Spa treatment
Description: A 40 minute period of lying in the spa treatment pool

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spa treatment
Description: A 40 minute period of lying in the spa treatment pool
Study: NCT06185049

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROCARE+ (Core intervention with add-on modules) and two booster sessions.
Description: The modules will primarily involve therapeutic sessions aimed at equipping adolescents with strategies for addressing risky situations, including enhancing their communication skills and developing coping mechanisms for stress management. The group sessions will also incorporate education on the importance of open discussions about thoughts, emotions, and behavior as integral components of emotional well-being, with a strong focus on offering support tailored to the identified risk factors. It will include two booster sessions at 6 and 12 months into the intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROCARE+ (Core intervention with add-on modules) and one booster session
Description: The modules will primarily involve therapeutic sessions aimed at equipping adolescents with strategies for addressing risky situations, including enhancing their communication skills and developing coping mechanisms for stress management. The group sessions will also incorporate education on the importance of open discussions about thoughts, emotions, and behavior as integral components of emotional well-being, with a strong focus on offering support tailored to the identified risk factors. It will include abooster sessions at 6 months into the intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROCARE+ (Core intervention with add-on modules) without booster sessions.
Description: The modules will primarily involve therapeutic sessions aimed at equipping adolescents with strategies for addressing risky situations, including enhancing their communication skills and developing coping mechanisms for stress management. The group sessions will also incorporate education on the importance of open discussions about thoughts, emotions, and behavior as integral components of emotional well-being, with a strong focus on offering support tailored to the identified risk factors.
Study: NCT04708145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection
Description: Intravitreal 2mg aflibercept injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection
Description: Intravitreal 2mg aflibercept injection
Study: NCT06052267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-56248
Description: Fluticasone Propionate/Salbutamol Sulfate. Oral inhalation powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-56248
Description: Fluticasone Propionate/Salbutamol Sulfate. Oral inhalation powder.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol sulfate
Description: Oral inhalation powder
Study: NCT05450692

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Participants will received docetaxel as an intravenous infusion.
Study: NCT06319482

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proactive CPAP Therapy
Description: CPAP machine uses Artificial Intelligence to make predictions and preventions of future apneic events to auto-adjust pressure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional APAP Therapy
Description: CPAP machine relies on the detection of respiratory events to determine how to react and auto-adjust pressure.
Study: NCT05320146

Intervention type: OTHER
Intervention: MRI-PDFF
Description: Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) is a MRI-based diagnostic imaging biomarker of the liver.

Intervention type: OTHER
Intervention: MRI-PDFF
Description: Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) is a MRI-based diagnostic imaging biomarker of the liver.
Study: NCT05816564

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM) for depression
Description: Both groups will be asked to engage in mindfulness activities but only one group will receive the train-positive ABM task. The control group will receive a sham task that is not programmed to train attention towards positive stimuli.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sham Attention Bias Modification (ABM)
Description: The sham intervention will be given to the control group (but they will still receive mindfulness exercises).
Study: NCT04666883

Intervention type: OTHER
Intervention: Review of records and follow up
Description: Follow up to identify patients who developed splenic hilar nodal metastases
Study: NCT05833880

Intervention type: BEHAVIORAL
Intervention: Self-administered questionnaire
Description: Self-administered questionnaire regarding complementary and alternative medicine use
Study: NCT05324215

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversalis fascia plane block and rectus sheath block
Description: Transversalis fascia plane block and rectus sheath block will be administered after the surgery.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intravenous fentanyl patient control device
Description: 24-hour fentanyl consumption will be recorded.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous fentanyl patient control device
Description: 24-hour fentanyl consumption will be recorded.